Cytokine-induced killer cell fusion to lower recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization sequentially combined with radiofrequency ablation: A randomized trial

National Medical Journal of China

Volumn 86, Issue 26, 2006, Pages 1823-1828

  Zhao, Ming ^a   Wu, Pei Hong ^a   Zeng, Yi Xin ^a   Xia, Jian Chuan ^a   Zhang, Fu Jun ^a   Xian, Li Jian ^a   Zhang, Yu Ping ^a   Zhou, Kun ^a   Fan, Wei Jun ^a   Zhang, Liang ^a   Gao, Fei ^a   Zhou, Qi Ming ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Killer cells; Liver neoplasms; Radiology, interventional

Indexed keywords

CYTOKINE; FLUORODEOXYGLUCOSE; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER RECURRENCE; CELL BASED GENE THERAPY; CELL FUSION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HEPATIC ARTERY; HEPATITIS B VIRUS; HUMAN; KILLER CELL; LIVER CELL CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL VEIN; POSITRON EMISSION TOMOGRAPHY; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK REDUCTION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEMIBODY IRRADIATION; HEPATITIS B VIRUS; HUMANS; KILLER CELLS; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 33748068501     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol, 2003, 9: 1885-1891.
2. Bloomston M, Binitie O, Fraiji E, et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg, 2002,68:827-831.
3. Chinese source. 2003,37:901-904.
4. Bruix J. Treatment of hepatocellular carcinoma Hepatology, 1997, 25: 259-262.
5. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma; a randomized trial. Lancet, 2000,356;802-807.
6. Chinese source. 2001,9:324.
7. Chinese source. 2003, 83:1053-1057.
8. Chinese source. 1999. 204-205.
9. Chinese source. 2003. 164-167.
10. Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg,2000, 232:381-391.
11. Chinese source. 2005,185:354-357.
12. Chinese source. 2003,37:870-871.
13. Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med,1991,174: 139-149.
14. Chinese source. 2004,29:333-335.
15. Chinese source. 2003,83:2049.
16. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood, 2004,103:777-783.
17. Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant, 2005,11:181-187.
18. Mehta BA, Schmidt-Wolf IG, Weissman IL, et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3 + CD56 + killer cells. Blood, 1995, 86: 3493-3499.